AptarGroup, Inc.

Equities

ATR

US0383361039

Non-Paper Containers & Packaging

Market Closed - Nyse 04:00:02 2024-03-27 pm EDT 5-day change 1st Jan Change
144.7 USD +1.02% Intraday chart for AptarGroup, Inc. +3.35% +17.02%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Aptargroup Insider Sold Shares Worth $284,906, According to a Recent SEC Filing MT
Aptargroup Insider Sold Shares Worth $499,932, According to a Recent SEC Filing MT
Wells Fargo Adjusts AptarGroup's Price Target to $160 From $157, Maintains Overweight Rating MT
Aptargroup Insider Sold Shares Worth $4,533,394, According to a Recent SEC Filing MT
Tanda, CEO of Aptar: Inflation less of a concern in the pharmaceutical sector MT
AptarGroup's Digital Health Business, Biogen to Develop Products for Neurological, Rare Diseases MT
Sector Update: Health Care Stocks Mixed Pre-Bell Friday MT
Transcript : AptarGroup, Inc., Q4 2023 Earnings Call, Feb 09, 2024
AptarGroup Q4 Adjusted Earnings, Sales Rise; Sets Q1 Outlook MT
Earnings Flash (ATR) APTARGROUP Posts Q4 Revenue $838.5M, vs. Street Est of $842.5M MT
Earnings Flash (ATR) APTARGROUP Posts Q4 EPS $1.21, vs. Street Est of $1.12 MT
Tranche Update on AptarGroup, Inc.'s Equity Buyback Plan announced on April 18, 2019. CI
AptarGroup, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
AptarGroup Maintains Quarterly Dividend at $0.41 per Share, Payable Feb. 22 to Stockholders of Record Feb. 1 MT
AptarGroup, Inc. Declares Quarterly Cash Dividend, Payable on February 22, 2024 CI
Transcript : AptarGroup, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 10:30 AM
North American Morning Briefing : S&P 500 Futures -2- DJ
Baird Upgrades AptarGroup to Outperform From Neutral, Raises Price Target to $150 From $125 MT
AptarGroup, Inc. Wins US FDA Contract to Study Opportunities for Low Global Warming Potential Propellants for Metered Dose Inhalers CI
Aptargroup Insider Sold Shares Worth $306,447, According to a Recent SEC Filing MT
AptarGroup, Inc. Seeks M&A CI
Transcript : AptarGroup, Inc., Q3 2023 Earnings Call, Oct 26, 2023
AptarGroup Posts Higher Q3 Adjusted Earnings, Sales; Issues Q4 EPS Outlook MT
AptarGroup, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023 CI
Tranche Update on AptarGroup, Inc.'s Equity Buyback Plan announced on April 18, 2019. CI
Chart AptarGroup, Inc.
More charts
AptarGroup, Inc. is engaged in designing and manufacturing of drug and consumer product dosing, dispensing and protection technologies. The Company serves various end markets, including pharmaceutical, beauty, food, beverage, personal care and home care. The Company operates through three segments: Aptar Pharma, Aptar Beauty and Aptar Closures. Aptar Pharma segment supplies nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and healthcare markets worldwide and supplies elastomer for injectable primary packaging components worldwide. The segment also provides services designed to accelerate and de-risk the development and regulatory approvals of drugs using drug delivery devices. The Aptar Beauty segment sells a variety of pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care and home care markets. Aptar Closures segment primarily sells dispensing closures.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
144.7 USD
Average target price
147.7 USD
Spread / Average Target
+2.08%
Consensus
  1. Stock
  2. Equities
  3. Stock AptarGroup, Inc. - Nyse
  4. News AptarGroup, Inc.
  5. Deutsche Bank Adjusts AptarGroup's Price Target to $148 From $158, Maintains Buy Rating